Relay Therapeutics, Inc.

Relay Therapeutics (RLAY) shows no cyber incidents or red-flag 8-K filings in our 90-day monitoring window, suggesting operational stability in the recent quarter. However, low signal in a compressed timeframe does not establish comprehensive risk coverage; the biotech sector faces structural pressures around financing, equity dilution, and clinical-stage cash burn that require deeper analysis. The full $49 Report pulls 12 months of SEC filings, quantifies dilution risk, maps financing history and runway, and flags AI-related execution risks specific to the company's platform. The full $49 Report adds quantified dilution scoring, 12-month financing context, and AI execution risk signals absent from headline monitoring.